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We report two antibodies, scFv 13B1 and MAb PD1.37, against the hinge regions of LHR and TSHR,
respectively, which have similar epitopes but different effects on receptor function. While neither
of them affected hormone binding, with marginal effects on hormone response, scFv 13B1 stimu-
lated LHR in a dose-dependent manner, whereas MAb PD1.37 acted as an inverse agonist of TSHR.
Moreover, PD1.37 could decrease the basal activity of hinge region CAMs, but had varied effects
on those present in ECLs, whereas 13B1 was refractory to any CAMs in LHR. Using truncation
mutants and peptide phage display, we compared the differential roles of the hinge region cysteine
box-2/3 as well as the exoloops in the activation of these two homologus receptors.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction revealed that unlike the hinge regions of TSHR and FSHR, LHRAlthough the mechanism of signaling in all three GpHRs follows
similar paths, vis-à-vis binding of the hormone to the exodomain
LRRs followed by the transduction of signal to the TMD via the
hinge region [1], ligand independent receptor activation in these
receptors vary widely. On one hand, TSHR is characterized by high
level of basal cAMP production and elevated susceptibility to
activating mutations [2], negligible basal receptor activation has
been observed in the case of LHR [3]. Previous reports of hor-
mone-independent stimulation of FSHR by hinge region antibodies
(aa 296–331) [4] and the inverse agonism displayed by TSHR MAb,
speciﬁc to residues 273 and 274 [5], is indicative of either a unique
attribute of individual hinge regions or a dual role played by the
interplay between subdomains in the hinge region. Such unique
agonistic, inverse agonistic or even antagonistic antibodies against
LHR hinge region are not known although truncation studies havechemical Societies. Published by E
ptor; LHR, lutropin receptor;
ing hormone; hCG, human
CL, extracellular loops; MAb,
ariable; CAM, constitutively
he).hinge does not play role in maintenance of receptor basal activa-
tion [3]. Notwithstanding, it is interesting that all three receptors
are activated by mutations in conserved patch in the hinge region
especially serine in the N-terminal region of Cb-2 subdomain [6].
This would suggest that even with their differences this region
might have a common role in receptor activation process.
In order to provide a better understanding of the role of hinge
region in LHR and compare its mechanism of action to TSHR, we
have isolated a panel of single chain fragment variables (scFvs)
against the LHR hinge region from the Tomlinson’s I and J human
scFv libraries as well as monoclonal antibodies against the TSHR
hinge region and investigated their effect on basal and hormone
stimulated activity in wild type and constitutively active mutants.2. Materials and methods
2.1. LHR/TSHR hinge region proteins
The hinge region of LHR (LHR-HinR, aa 265–355) and TSHR
(TSHR-HinR aa 261–413) were cloned as N-terminal His-Tag pro-
tein, puriﬁed using IMAC chromatography (Ni-Sepharose) and their
purity ascertained by immunoblot analysis using anti-His-Tag
antibodies (Fig. S1).lsevier B.V. All rights reserved.
Fig. 1. Effect receptor antibodies on hormone–receptor interactions. Hinge region antibodies (50 lg/ml) were preincubated with HEK293-TSHR/LHR membrane preparation
at 37 C followed by addition of 0.14 nM 125I-hCG/hTSH (speciﬁc activity of the tracer – 0.2 lCi/fmol) and bound hCG-LHR (A(i)) or hTSH-TSHR (B(i)) was determined. Effect
on basal and hormone stimulated response was determined by preincubating the antibodies (50 lg/ml) with HEK293-LHR or TSHR cells alone (A(ii) and B(ii)), respectively or
subsequently followed by addition of (A(iii)) hCG (1nM) & (B(iii)) hTSH (5 nM), respectively and cAMP produced determine by RIA as described by Saha & Majumdar et al.
[18]. (C) Dose dependent decrease of cAMP production by HEK293-TSHR cells in presence of increasing concentration of MAb PD1.37 or (D) increase in cAMP production of
HEK293-LHR cells in presence of scFv13B1. Neutral antibodies were used as controls for each case. Statistical signiﬁcance was compared to the control and is denoted by the
P-value calculated from the two-tailed unpaired t-test.
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MAbs against the TSHR-HinR protein were developed according
to protocol discussed previously [7]. ScFvs against LHR-HinR
protein were selected from Phage human ScFv library (Tomlinson’s
I + J library) as described previously [8]. Soluble ScFvs were puri-
ﬁed by Protein A afﬁnity chromatography. All antibodies thus
generated were characterized for speciﬁc binding to their cognate
antigen fragment, and to their cognate full-length receptor through
ELISA and ﬂowcytometry.2.3. TSHR/LHR WT and mutated constructs
Full length wild type (WT) LHR and TSHR deletion as well as
TSHR–LHR chimeric constructs [9] were kind gift of Dr. PremaNara-
yan and Prof. Basil Rapoport, respectively. TSHR and LHRmutations
were created using a single step PCR based mutagenesis protocol
[10]. Transient transfection of different TSHR/LHR constructs were
carried out simultaneously in parallel plates to determine the li-
gand binding, cAMP production, and ﬂowcytometric analysis, using
Lipofectamine 2000 reagent as per the manufacturer’s protocol
Fig. 2. Effect scFv 13B1 on LHR activating mutation and chimeric mutants. Binding of scFv13B1 to HEK293 cells transfected with the (A(i)) wild type or (A(ii)) S277Q or (B(i))
TSH-LHR-6 constructs was monitored in ﬂow cytometry using protocols discussed in the legends of Fig. S3. Mock transfected cells (shaded histograms) were used as controls.
scFv 13B1 (50 lg/ml) was added to HEK293 cells transfected with either (A(iii)) S277Q or (B(ii)) TSH-LHR-6 and total cAMP produced was measured by RIA. cAMP produced
was normalized to the surface expression of LHR constructs with respect to wild type as determined by binding of LHR LRR 1–3 speciﬁc antibody in ﬂowcytometry (data not
shown).
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or LHR (HEK293-LHR) were similarly created and selected based
on their ability to speciﬁcally bind radiolabeled hormone and exhi-
bit cAMP production in response to the hormone.
2.4. Receptor binding and in vitro bioassay
The effect of various antibodies on hormone action was investi-
gated by incubating cells (stable cell line or transiently transfected)
or their membrane preparations with different dilutions of
antibodies prior to the addition of labeled or unlabeled ligand.
Measurement of hormone bound receptors or cAMP produced in
presence of the antibodies were done as previously described [4].
2.5. Flow cytometric analysis of TSHR/LHR mutants
Cell surface expression of different TSHR/LHR mutants and
identity/location of putative epitopes of receptor antibodies
was assessed by ﬂowcytometry using standard protocol [11] at
low temperature and analyzed in FACSCANTO-II ﬂowcytometer.
Antibody binding (median ﬂuorescence intensity – MFI) of a given
antibody was normalized to a negative control and expressed as
relative MFI (RMFI).
2.6. Peptide phage display
The epitope of scFv 13B1 was identiﬁed using the Ph.D.-12
phage-display peptide library (NEB Inc.) according to manufac-
turer’s instructions. The sequences of the dodecapeptides appearing
more than twice in the selected phage clones were classiﬁed as theconsensus sequence, scanned against the full length LHR sequence
with non-stringent gap opening and extension penalties (5 and
20, respectively in ClustalW 2.0.12) to determine putative binding
site.
3. Results
3.1. Effect of receptor antibodies on hormone binding and receptor
activation
Screening of Tomlinson I + J ScFv library yielded ten unique
LHR-HinR speciﬁc scFvs, as determined by their CDR signatures
(Fig. S2), of which four ScFvs with higher binding to LHR-HinR
were further characterized. Four out of the nine TSHR MAbs, found
to be positive for TSHR-HinR protein binding, were similarly
chosen based on their higher binding and speciﬁcity to their cog-
nate receptor as determined by ELISA (Figs. S3A and S3B) and ﬂow-
cytometric analysis (Fig. S3C).
Hormone binding to HEK293-TSHR/LHR membranes or cAMP
produced in these cells in response to hormones was measured
in presence or absence of receptor antibodies to investigate their
effect on hormone action. Out of the four LHR-HinR speciﬁc anti-
bodies, only 13F3 could inhibit hormone binding (Fig. 1A(i)) as well
as receptor activation (Fig. 1A(iii)), whereas in case of TSHR, mar-
ginal or no inhibition of hormone binding was observed
(Fig. 1B(i)), although MAb PD1.37 and MAb PE3.51 showed signif-
icant inhibition of hormone response (Fig. 1B(iii)). Most interest-
ingly, the MAb PD1.37 in absence of the hormone, could inhibit
the basal cAMP production of TSHR (Fig. 1C), whereas scFv 13B1
showed dose dependent increase in LHR stimulation (Fig. 1D). In
Fig. 3. Effect MAb PD1.37 on TSHR hinge region mutations. Binding of PD1.37 to
HEK293 cells transfected with the wild type or (A(i)) S281I or (A(ii)) D410N mutant
was monitored by ﬂow cytometry using protocols discussed in the legends of
Fig. S3. (B) Effect of PD1.37 (50 lg/ml) on basal and hormone stimulated activation
of S281I and D410N mutants. cAMP produced was normalized to the surface
expression of TSHR mutants with respect to wild type as determined by binding of
TSHR LRR 1–3 MAb 413.1.F7 in ﬂowcytometry, as shown in panel 3A.
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saturating concentration of hCG (Fig. 1A(iii)), suggesting non-over-
lap of hormone binding and scFv epitopes.
3.2. Effect of antibodies on receptor mutants
Basal and hormone stimulated response of TSHR/LHR mutants
in presence of PD1.37/13B1 and their binding to these mutants
was normalized to the surface expression of each mutant with re-
spect to the WT by ﬂowcytometry using a control LRR 1–3 speciﬁc
TSHRMAb 413.1.F7 or polyclonal antibody speciﬁc to LHR LRR 1–3.Although scFv 13B1 displayed binding to the hinge region CAM
S277Q (Fig. 2A(ii)) equivalent to theWT (Fig. 2A(i)) in a ﬂowcytom-
etric analysis, it was not only unable to stimulate the high basal
cAMP of the mutant, but displayed a marginal decrease in cAMP
basal similar to the neutral antibody 13F1, further suggesting that
the epitope of 13B1 may be sensitive to hormone independent
changes in LHR-HinR (Fig. 2A(iii)). On the other hand, the scFv
could not only bind to chimeric receptor TSH-LHR-6 (replacement
of TSHR Hinge by that of LHR) (Fig. 2B(i)), it was also able to stim-
ulate the chimera, although fold stimulation in TSH-LHR-6 was
found to be less than that of the WT (Fig. 2B(ii)).
Similar to 13B1, binding of PD1.37 to the LHR S277Q homolog in
TSHR (S281I) (Fig. 3A(i)) as well as the inactivating mutation,
D410N (Fig. 3A(ii), was found to be comparable to that of the
WT. In contrast to the TSHR-HinR mutants, the ECL CAMs, I486F,
I568T or V656F, residing in the exoloops 1, 2 and 3 respectively,
showed differential binding to PD1.37 (Fig. 4A). In order to quan-
tify the differences in binding, ratios of the normalized binding
(RMFI) of each mutant and the WT was considered and it was
observed that PD1.37 has a lower binding to I486F and I568T when
compared to the control MAb 413.1.F7 but displays higher binding
to V656F (Fig. 4B).
Interestingly, unlike 13B1, PD1.37, affected the high basal of
S281I and decreased both hormone dependent and independent
cAMP production in this mutant, but did not affect the inactivating
mutation, D410N (Fig. 3B). However, although PD1.37 displayed
higher binding to V656F, it could not decrease the basal cAMP pro-
duction in this mutant, whereas marked decrease was observed in
case of I486F which exhibited comparatively lower MAb binding
(Fig. 4C).
3.3. Epitope mapping of receptor antibodies
Binding of PD1.37 to progressive deletion mutants of TSHR was
monitored in ﬂowcytometry to establish the epitope of the anti-
body, as shown in Fig. 5. The binding of PD1.37 to D287–366
was slightly lower than that of the WT, whereas considerable loss
of binding was observed for D287–376 and total loss of binding for
D287–384. This would suggest that the epitope of PD1.37 could be
in the region of residues 366–384 around the Cb-3 of the TSHR-
HinR. The epitope of scFv 13B1 was expected to be around the
Cb-2 region of LHR due to its insensitivity to critical S277Q mutant.
This was conﬁrmed by screening the peptide phage-display library
with the puriﬁed 13B1. Comparison between the consensus amino
acid sequence derived from these phages, (Fig. 6A) and LHR
revealed a discontinuous epitope with a strong sequence similarity
(>70% similarity) at aa 291–298 in Cb-2 and a second seed se-
quence at aa 331–334/338–339 in Cb-3 region (Fig. 6B).4. Discussion
The GpHR hinge regions are thought to physically constrain the
exoloops of receptors maintaining them in a low basal state. CAMs,
hormonal stimulation, as well as agonistic antibodies disrupt these
interactions as the initial events in receptor activation [1]. Interest-
ingly, the role of LHR hinge region in maintenance of basal cAMP
has been debated as the removal of its ECD does not result in
increase in basal cAMP levels unlike TSHR/FSHR [3]. Moreover,
the absence of any previous reports of agonistic LHR-HinR antibod-
ies, unlike those of TSHR/FSHR, further supports the above hypoth-
esis. Isolation of antagonistic (13F3) as well as agonistic (13B1)
antibodies against LHR-HinR indicate its role in both hormone
binding as well as its ability to affect hormone independent recep-
tor activation. In contrast TSHR-HinR antibodies (PD1.37, PE3.51)
inhibited hormone response but had marginal effect on hormone
Fig. 4. Effect MAb PD1.37 on basal activity of TSHR ECL CAMs. (A) Flow cytometric analysis of HEK293 cells transfected with the wild type or different ECL mutants with
control MAb 413.1.F7 (right panel) or with MAb PD1.37 (left panel). Dotted lines and values in boxes denote MFIs of constructs and the solid line that of the mock transfected
control. (B) Ratios of RMFI of each ECL mutant with respect to wild type as determined by the control antibody (gray bar) or PD1.37 (black bar) (C) Effect of PD1.37 on basal
activation of ECL mutants. cAMP produced was normalized as described in panel 3B.
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volved in hormone binding, a possibility speculated previously [6].
In addition MAb PD1.37 acted as an inverse agonist by decreas-
ing the basal cAMP production similar to those reported for MAb
CS-17 [12] and human MAb 5C9 [13]. However, unlike CS-17 or
5C9, PD1.37 does not compete for the hormone and is purely a
hinge region speciﬁc antibody. Moreover, CS-17 and 5C9 were
shown to decrease the high basal of the hinge region CAM S281I
as well as those present in ECLs such as I486F, I568T or V656F.
Mechanism of inhibition of basal cAMP production of these CAMs
have been thought to be stabilization of the receptor inactive state
by suppressing conformational changes in the hinge region of
these CAMs [14]. Similar conclusions may also be drawn for
PD1.37, as this antibody decreased the hormone dependent and
independent activity of S281I, but interestingly did not affect
hormone stimulation of the inactivating mutation D410N, proba-
bly due to similar conformational selection of the mutant by the
antibody. The effect of PD1.37 on exoloop mutants differed mark-
edly from CS-17; PD1.37 displayed lower binding to the ﬁrst andsecond exoloop mutants but had higher binding towards the third.
This would indicate that the epitope of PD1.37 (aa 366–384) is sen-
sitive to conformational changes caused by CAMs in ECL 1 and 2,
whereas activating mutation in ECL 3 causes a reversal of this sen-
sitivity making the antibody more accessible to the receptor. More
interestingly, Rapoport and co-workers, based on deletions in
TSHR-HinR, have proposed that aa in the vicinity of 371–384
may be involved in inverse agonistic feature of the hinge region
[14]. A corollary to this would be a plausible interaction of Cb-3
residues with the exoloop 3 as a negative regulator of hormone
independent receptor activation.
Interestingly, unlike PD1.37, the LHR agonistic scFv 13B1 had no
effect on S277Q mutant suggesting that its epitope is sensitive to
the conformational changes in the Cb-2 region. The additive effect
of 13B1 and hormone action suggests that the conformational
change in this epitope may be independent of those brought about
by the hormone. Such a possibility is further veriﬁed by the ability
of 13B1 to stimulate the TSH-LHR-6 which responds to TSH but not
to hCG.
Fig. 5. Epitope mapping of MAb PD1.37. Putative binding site of PD1.37 was mapped by its ability to bind to different TSHR hinge region deletions in ﬂowcytometry. Left
panel – control MAb 413.1.F7, Right panel MAb – PD1.37. Dotted lines denote MFIs of constructs and solid line for the mock transfected control.
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both Cb-2 and Cb-3 suggests a close spatial proximity of these
two subdomains, as represented in Fig. 7. Indeed it has been pro-
posed that the Cb-2 and Cb-3 of GpHRs are disulﬁde bonded, in
close proximity and may constitute conformationally anchored re-
gions [15] and epitope analysis of 13B1 provide tentative experi-
mental evidence of such. Moreover, the Y-E/D-Y motif in Cb-3that form the second seed sequence of 13B1 epitope is known to
be tyrosine sulfated and mutations in these tyrosine residues
makes the receptor, signaling and binding sensitive [15,16]. The
presence of loss-of-function mutations like C390W, D403N and
D410N in TSHR and E354K and C343S in LHR around Cb-3 as op-
posed to activating mutations in the N-terminal of hinge region
hint at a cooperative involvement of the Cb-2 and Cb-3 regions
Fig. 6. Epitope mapping of scFv 13B1 by peptide phage display analysis. (A). Nucleotide sequences deduced from the phage clones selected after three rounds of biopanning.
Three groups of sequences were obtained on analyzing the sequence of phage clones and consensus from them. The numbers in the parentheses denote the frequency or ratio
of the number of the phage clones with common sequence. (B). Sequence alignment of the translated consensus sequence, derived from the phage clones, with the LHR HinR
sequence. Residues marked by (⁄) denotes identical residues, denoted by (:) marks conserved substitutions and those by (.) denotes semi-conserved substitutions.
Fig. 7. Schematic representation of the epitopes of scFv 13B1 and MAb PD1.37. A
generic model of the glycoprotein hormone receptor exodomain comprising of the
N-terminal leucine rich repeats [adapted from TSHR LRR domain-MAb M22 crystal
structure (PDB ID: 3GO4)], Cb-2, Cb-3 and Cb-2/3 linker is shown. 50 aa insertion in
TSHR is shown in dotted lines. Residues marking the putative beginning and end of
the hinge region are shown as gray spheres and residues marking those of the
putative epitope of scFv 13B1 by black sphere. Light-gray arrows show Cb-2 and Cb-
3 regions and dark-gray arrow the putative epitope of MAb PD1.37. (Image is not to
scale). Epitopes of previously characterized inverse agonistic TSHR MAb CS-17 is
also mentioned.
816 R. Majumdar et al. / FEBS Letters 586 (2012) 810–817which act in concert to maintain the basal cAMP production
[17].
In conclusion, we report an inverse agonistic MAb of TSHR
that does not compete for hormone binding and preferentially sup-
presses exodomain CAMs and for the ﬁrst time, an agonistic scFv of
LHR providing, deﬁnitive evidence of the role of LHR HinR in hor-
mone independent receptor activation. These antibodies may
prove to be valuable tools as therapeutic agents in toxic adenomas
arising due to TSHR CAMs as well as provide insight into structure–
activity relationship of LHR mutants causing precocious puberty.
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